why choose us

First received: July 19, 2022

Clinical Trial: Testing P2Y12 Platelet Inhibitors Generics Beyond Bioequivalence

Study Status: Completed

Recruit Status: Completed

Condition: Cardiovascular Diseases
Acute Coronary Syndrome

Study Type: Interventional


Official Title: Testing P2Y12 Platelet Inhibitors Generics Beyond Bioequivalence: A Parallel Single-blinded Randomized Trial

Brief Summary: This is a pilot study that was conducted to prove the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers. we advocate comparing the clinical efficacy rather than simple bioequivalence comparison.

Read more